• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EIGR

    Eiger BioPharmaceuticals Inc.

    Subscribe to $EIGR
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: eigerbio.com

    Recent Analyst Ratings for Eiger BioPharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    8/9/2021$26.00 → $27.00Buy
    Citigroup
    See more ratings

    Eiger BioPharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kayne Richard A bought $72,815 worth of shares (278,239 units at $0.26) (SEC Form 4)

      4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      11/2/23 9:21:30 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kawas Leen bought $6,375 worth of shares (24,332 units at $0.26) (SEC Form 4)

      4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      11/2/23 9:14:42 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Eiger BioPharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      5/10/24 2:14:57 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      2/14/24 4:03:08 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      2/14/24 10:55:55 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      SC 13D/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      12/4/23 6:01:01 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Eiger BioPharmaceuticals Inc.

      SC 13D - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      11/24/23 6:01:01 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      SC 13D/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      11/2/23 9:54:09 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Eiger BioPharmaceuticals Inc.

      SC 13D - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      10/20/23 4:29:11 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      9/28/23 4:54:38 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Eiger BioPharmaceuticals Inc.

      SC 13G - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      8/15/23 6:00:25 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

      4/18/23 9:59:46 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Eiger BioPharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Eiger BioPharmaceuticals Inc.

      8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      5/8/24 5:00:57 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Eiger BioPharmaceuticals Inc.

      8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      5/2/24 4:32:02 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

      10-K/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/29/24 4:33:07 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Eiger BioPharmaceuticals Inc.

      10-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/8/24 5:19:20 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Eiger BioPharmaceuticals Inc.

      8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/3/24 4:45:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-K filed by Eiger BioPharmaceuticals Inc.

      NT 10-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/1/24 5:00:49 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Eiger BioPharmaceuticals Inc.

      S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/1/24 4:58:05 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Eiger BioPharmaceuticals Inc.

      S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/1/24 4:55:56 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Eiger BioPharmaceuticals Inc.

      S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/1/24 4:56:58 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Eiger BioPharmaceuticals Inc.

      S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

      4/1/24 4:54:30 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Eiger BioPharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kayne Richard A bought $72,815 worth of shares (278,239 units at $0.26) (SEC Form 4)

      4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      11/2/23 9:21:30 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kawas Leen bought $6,375 worth of shares (24,332 units at $0.26) (SEC Form 4)

      4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      11/2/23 9:14:42 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Kayne Richard A claimed ownership of 5,096,986 shares (SEC Form 3)

      3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      10/30/23 4:53:52 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Kawas Leen claimed ownership of 4,367,100 shares (SEC Form 3)

      3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      10/30/23 4:51:30 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Choong Ingrid

      4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      9/5/23 9:38:59 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Choong Ingrid claimed ownership of 33,500 shares

      3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      9/5/23 9:35:36 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Apelian David

      4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      7/6/23 5:37:37 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Vollins James

      4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      5/2/23 4:30:36 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Vollins James

      3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      4/14/23 6:44:05 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Kachioff William G

      3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

      4/14/23 6:42:03 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Eiger BioPharmaceuticals Inc. Financials

    Live finance-specific insights

    See more

    Eiger BioPharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

      Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor

      6/29/23 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

      Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at

      6/28/23 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022

      Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV. The live and replayed webcast of the call will be available through the company's websi

      12/7/22 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

      Phase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in DecemberPhase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling PatientsPhase 3 Congenital Hyperinsulinism Avant (avexitide) Program InitiatedStrong Cash Position: $121.0 Million in Cash, Cash Equivalents, and Total InvestmentsPALO ALTO, Calif., Nov. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for third quarter 2022 and provided a business update.

      11/3/22 4:01:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3

      -  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website at www.eig

      10/24/22 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

      Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA ApplicationPhase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year EndPhase 3 Congenital Hyperinsulinism AVANT (avexitide) Program InitiatedApproval of Zokinvy in Europe; Partnership with AnGes in JapanStrong Cash Position: $141.8M Cash, Cash Equivalents, and Total InvestmentsPALO ALTO, Calif., Aug. 4, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) infection and other serious diseases, today reported financial results for second quarter 2022 and provided a business

      8/4/22 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4

      -  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, August 4, 2022 at 4:30 PM ET to discuss its second quarter 2022 financial results and provide a business update.  The live and replayed webcast of the call will be available through the company's website at www.eig

      7/28/22 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

      Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year EndZokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Year EndStrong Cash Position: $153.5M Pro Forma CashPALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2022 and provided a business update.

      5/5/22 4:06:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5

      -  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website

      4/21/22 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study

      Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary endpoint achieved across multiple SARS-CoV-2 variants, including omicron Eiger plans to submit data to FDA for Emergency Use Authorization (EUA) Management to host conference call today at 8:30 AM ET PALO ALTO, Calif., March 17, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announce

      3/17/22 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cutera Appoints Stephana Patton as Chief Legal Officer

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

      11/13/23 8:30:00 AM ET
      $CUTR
      $EIGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

      PALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock. The stock option was approved by the Compensation Committee of Eiger's Board of Directors and granted under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan, as amended, with a grant date of April 30, 2023, as an

      5/3/23 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

      PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones. "This is a pivotal year for Eiger as we plan for topline data from the landmark D-LIVR study by year end.  D-LIVR is the largest trial conducted in HDV and if positive will support re

      1/6/22 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer

      PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik Atkisson as the Company's General Counsel and Chief Compliance Officer. Mr. Atkisson brings over twenty years of experience to Eiger, and was most recently Chief Compliance Officer, Legal Counsel, and Privacy Officer at Cytokinetics, Incorporated, where he was responsible for legal matter

      9/21/21 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors

      PALO ALTO, Calif., April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Kim Sablich to its Board of Directors.  Ms. Sablich is a pharmaceutical industry veteran with broad commercial experience spanning over two decades in large pharma and biotechnology companies, including vaccines and prescription products across diverse therapeutic areas, and rare and ultra-rare disease programs.  Ms. Sablich is currently Executive Vice President, General Manager, North America at Jazz Pharmaceuticals

      4/22/21 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Eiger BioPharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

      Announces "Stalking Horse" Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a "stalking horse" agreement for the sale of Zokinvy® (lonafarnib) to Sentynl Therapeutics, Inc., a biopharmaceutical company focused on rare diseases. Under the terms of the "stalking horse" agreement, subject to court

      4/1/24 11:12:41 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

      Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone payment from AnGesZokinvy approved in the U.S. (2020), 30 European countries (2022), and now Japan (2024)PALO ALTO, Calif., Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchin

      1/18/24 5:49:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split

      PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The Company's common stock will begin trading on a post-split basis at the market open on January 8, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requireme

      1/4/24 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cutera Appoints Stephana Patton as Chief Legal Officer

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

      11/13/23 8:30:00 AM ET
      $CUTR
      $EIGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

      PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety Monitoring Board (DSMB) for the study following its quarterly safety review. In a communication dated September 7, 2023, the DSMB recommended the discontinuation of the LIMT-2 study due to observations of four patients with hepatobiliary events that resulted in liver decompe

      9/12/23 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

      PALO ALTO, Calif., Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY. Eiger will also host one-on-one meetings with investors at the conference. The presentation will be available on the Investors section of the

      9/5/23 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

      Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024David Apelian, MD, PhD, MBA, appointed CEOPALO ALTO, Calif., Aug. 14, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the second quarter 2023 and provided a business update.

      8/14/23 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

      Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor

      6/29/23 8:00:00 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

      Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at

      6/28/23 4:05:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

      Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2Phase 3 HI AVANT (avexitide) Program: Startup Activities InitiatedCash Position: $75.3 million in Cash, Cash Equivalents, and Short-Term Debt Securities as of March 31, 2023PALO ALTO, Calif., May 11, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2023 and provided a business update.

      5/11/23 4:00:00 PM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Eiger BioPharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup reiterated coverage on Eiger BioPharmaceuticals with a new price target

      Citigroup reiterated coverage of Eiger BioPharmaceuticals with a rating of Buy and set a new price target of $27.00 from $26.00 previously

      8/9/21 8:38:42 AM ET
      $EIGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care